Mean Platelet Volume as a Prognostic Marker in Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Combined Chemotherapy

Tuncel, Tolga; Ozgun, Alpaslan; Emirzeoglu, Levent; Celi̇k, Serkan; Bilgi, Oğuz; Karagöz, Bülent

doi:10.7314/apjcp.2014.15.15.6421

Cited by 46 publications

(50 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar evidence was provided by another retrospective study in patients with metastatic colorectal cancer [11], in that disease progression was found to be significantly reduced in patients with lower MPV values (HR: 0.41; 95% CI: 0.17-0.98). Interestingly, increased platelet size was also found to be a significant predictor of hepatocellular carcinoma in patients with chronic liver disease (area under the curve: 0.676; 95% CI: 0.580-0.773), performing even better than other and most used biomarkers of prognosis, such as alphafetoprotein [12].…”

Section: Mean Platelet Volume In Health and Diseasesupporting

confidence: 83%

Platelets and immunity: the interplay of mean platelet volume in health and disease

Lippi

Franchini

2015

Expert Review of Hematology

View full text Add to dashboard Cite

Section: Mean Platelet Volume In Health and Diseasesupporting

confidence: 83%

Platelets and immunity: the interplay of mean platelet volume in health and disease

Lippi

Franchini

2015

Expert Review of Hematology

View full text Add to dashboard Cite

“…The same study also found that, among metastatic subjects included, bevacizumab therapy was more beneficial for those with a lower MPV in terms of progression-free survival (HR: 0.41). 26 In our study, which included non-metastatic patients only, we expected a higher preoperative MPV for relapse-free patients than the relapsed in line with previous studies but we could not detect a significant difference. However, we observed that MVP fell after the operation and displayed a tendency to increase at the time of relapse.…”

Section: Discussionsupporting

confidence: 69%

The Use of Neutrophil/Lymphocyte Ratio (Nlr), Platelet/Lymphocyte Ratio (Plr), and Mean Platelet Volume (Mpv) As Inflammatory Biomarkers in the Prognosis of Patients with Early-Stage Colorectal Adenocarcinoma

Kazaz¹

2017

UHOD

View full text Add to dashboard Cite

Colorectal cancer (CRC) represents the most prevalent cancer of the gastrointestinal system in adults. Despite long-term survival rates achieved by early resection and adjuvant therapies, relapse is a significant problem for those patients. The present study aims to investigate the possibility of using neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and mean platelet volume (MPV) as biomarkers for postoperative relapse in patients with CRC. We retrospectively analyzed 188 non-metastatic CRC patients followed up and treated at Dokuz Eylül University, Faculty of Medicine Hospital, Medical Oncology Clinic. We recorded demographic, laboratory and histopathological data from patient files and we calculated NLR, PLR and MPV, which were recorded as preoperative, postoperative and relapse values. This study classified patients into two groups: relapsed and relapse-free patients. Twenty-five patients (13.3%) developed a relapse during the follow-up period. The relapsed group had a higher NLR prior to tumor resection compared to the relapse-free patients, whereas PLR and MPV were not high. Despite the absence of any significant change in NLR or MPV after tumor resection, PLR displayed an upwards trend. At the time of relapse, CEA and MPV increased as PLR fell (compared to the postoperative period). The relapse-free group exhibited a significant decrease in CEA and MPV after tumor resection, and other parameters did not change. Comparing the results based on disease stages, stage III patients had significantly higher MPV levels than the stage II. NLR, MPV and PLR may help physicians identify prognosis after tumor resection in patients with CRC.

show abstract

“…10,12 This situation with different cytokines that have proinflammatory characteristics is very important for cancer patients. [18][19][20][21][22][23][24][25] However, Osada et al 18 reported that increased MPV level was very important in stomach cancer patients in compared with healthy subjects. 10,[12][13][14][15] Some studies did not find a relationship between MPV and platelet count as a prognostic factors in cancer patients.…”

Section: Discussionmentioning

confidence: 99%

Role of increased mean platelet volume (MPV) and decreased MPV/platelet count ratio as poor prognostic factors in lung cancer

Omar

Tanrıverdi

Cokmert

et al. 2017

Clinical Respiratory J

View full text Add to dashboard Cite

show abstract

Mean Platelet Volume as a Prognostic Marker in Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Combined Chemotherapy

Cited by 46 publications

References 17 publications

Platelets and immunity: the interplay of mean platelet volume in health and disease

Platelets and immunity: the interplay of mean platelet volume in health and disease

The Use of Neutrophil/Lymphocyte Ratio (Nlr), Platelet/Lymphocyte Ratio (Plr), and Mean Platelet Volume (Mpv) As Inflammatory Biomarkers in the Prognosis of Patients with Early-Stage Colorectal Adenocarcinoma

Role of increased mean platelet volume (MPV) and decreased MPV/platelet count ratio as poor prognostic factors in lung cancer

Contact Info

Product

Resources

About